Baxter Receives U.S. FDA Approval for 0.9% Sodium Chloride Injection
News May 22, 2015
Baxter International Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental drug application to establish its Sabinanigo, Spain, facility as an approved manufacturing site for 0.9% Sodium Chloride Injection, USP, for the U.S. market.
The approval includes product presentations in 250 mL, 500 mL and 1000 mL, which Baxter has been distributing in the U.S. to alleviate a drug shortage with the knowledge of the FDA. All three of these product presentations of 0.9% Sodium Chloride Injection, USP, more commonly known as saline, have been listed in drug shortage databases maintained by FDA and the American Society of Health-System Pharmacists over the past two years.
"The approval of an additional manufacturing site for Sodium Chloride Injection in the U.S. gives us greater flexibility to respond to market demand fluctuations and will help as we continue to meet patient and healthcare provider need for this critical product," said Brik Eyre, president of Baxter's Hospital Products business.
Eyre continued, "FDA was quick to recognize the benefit of addressing industry demand for sterile IV solutions in collaboration with companies like Baxter. This approval illustrates the strength of Baxter's global manufacturing network, as well as our commitment to meeting important healthcare needs."
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu VaccineNews
Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.READ MORE
Key to Creating Better Medicines with Less Side EffectsNews
A new study published in Science by Professors Yossi Paltiel of the Hebrew University of Jerusalem and Ron Naaman from the Weizmann Institute of Science describes a breakthrough technology with the power to create drugs with fewer unwanted side effects.
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018